Correlation Between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus Aureus

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2006 Feb 24

PMID 16495273

Citations 154

Authors

Longzhu Cui

Eiji Tominaga

Hui-Min Neoh

Keiichi Hiramatsu

Affiliations

Soon will be listed here.

Abstract

We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA). This correlation is related to cell wall thickening, suggesting that, similar to the case with vancomycin resistance in VISA, the physical barrier of a thickened cell wall may contribute to daptomycin resistance in S. aureus.

Citing Articles

Resistance phenotype and genetic features of a heterogeneous vancomycin intermediate-resistant Staphylococcus aureus strain from an immunocompromised patient.

Cheng X, Wang Y, Ma J, Ma L, Sun W, Su J Braz J Microbiol. 2023; 55(1):323-332.

PMID: 38057692 PMC: 10920550. DOI: 10.1007/s42770-023-01192-y.

Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin.

Kebriaei R, Abdul-Mutakabbir J, Stamper K, Lev K, Rybak M Infect Dis Ther. 2023; 12(10):2485-2494.

PMID: 37798469 PMC: 10600059. DOI: 10.1007/s40121-023-00875-1.

Comparative Genomics Identifies Novel Genetic Changes Associated with Oxacillin, Vancomycin and Daptomycin Susceptibility in ST100 Methicillin-Resistant .

Di Gregorio S, Haim M, Famiglietti A, Di Conza J, Mollerach M Antibiotics (Basel). 2023; 12(2).

PMID: 36830286 PMC: 9952151. DOI: 10.3390/antibiotics12020372.

Growth Arrest of Staphylococcus aureus Induces Daptomycin Tolerance via Cell Wall Remodelling.

Ledger E, Edwards A mBio. 2023; 14(1):e0355822.

PMID: 36722949 PMC: 9973334. DOI: 10.1128/mbio.03558-22.

Transiently silent acquired antimicrobial resistance: an emerging challenge in susceptibility testing.

Wagner T, Howden B, Sundsfjord A, Hegstad K J Antimicrob Chemother. 2023; 78(3):586-598.

PMID: 36719135 PMC: 9978586. DOI: 10.1093/jac/dkad024.

References

Hiramatsu K . Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2002; 1(3):147-55. DOI: 10.1016/S1473-3099(01)00091-3. View

Cui L, Ma X, Sato K, Okuma K, Tenover F, Mamizuka E . Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol. 2003; 41(1):5-14. PMC: 149586. DOI: 10.1128/JCM.41.1.5-14.2003. View

Hiramatsu K, Cui L, Kuroda M, Ito T . The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2001; 9(10):486-93. DOI: 10.1016/s0966-842x(01)02175-8. View

Hiramatsu K, Cui L, Kuwahara-Arai K . Has vancomycin-resistant Staphylococcus aureus started going it alone?. Lancet. 2004; 364(9434):565-6. DOI: 10.1016/S0140-6736(04)16867-0. View

Hiramatsu K, Hanaki H, Ino T, YABUTA K, Oguri T, Tenover F . Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997; 40(1):135-6. DOI: 10.1093/jac/40.1.135. View

Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S . Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350(9092):1670-3. DOI: 10.1016/S0140-6736(97)07324-8. View

Mangili A, Bica I, Snydman D, Hamer D . Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005; 40(7):1058-60. DOI: 10.1086/428616. View

Cha R, Grucz Jr R, Rybak M . Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother. 2003; 47(5):1598-603. PMC: 153299. DOI: 10.1128/AAC.47.5.1598-1603.2003. View

Laganas V, Alder J, Silverman J . In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother. 2003; 47(8):2682-4. PMC: 166111. DOI: 10.1128/AAC.47.8.2682-2684.2003. View

10.

Tally F, Zeckel M, Wasilewski M, Carini C, Berman C, Drusano G . Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs. 2005; 8(8):1223-38. DOI: 10.1517/13543784.8.8.1223. View

11.

Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K . Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother. 2000; 44(9):2276-85. PMC: 90058. DOI: 10.1128/AAC.44.9.2276-2285.2000. View

12.

Cetinkaya Y, Falk P, Mayhall C . Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000; 13(4):686-707. PMC: 88957. DOI: 10.1128/CMR.13.4.686. View

13.

Schriever C, Fernandez C, Rodvold K, Danziger L . Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm. 2005; 62(11):1145-58. DOI: 10.1093/ajhp/62.11.1145. View

14.

Alder J . Daptomycin: a new drug class for the treatment of Gram-positive infections. Drugs Today (Barc). 2005; 41(2):81-90. DOI: 10.1358/dot.2005.41.2.882660. View

15.

Petersen P, Bradford P, Weiss W, Murphy T, Sum P, Projan S . In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother. 2002; 46(8):2595-601. PMC: 127327. DOI: 10.1128/AAC.46.8.2595-2601.2002. View

16.

Cui L, Lian J, Neoh H, Reyes E, Hiramatsu K . DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2005; 49(8):3404-13. PMC: 1196288. DOI: 10.1128/AAC.49.8.3404-3413.2005. View

17.

Akins R, Rybak M . Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in.... Antimicrob Agents Chemother. 2001; 45(2):454-9. PMC: 90312. DOI: 10.1128/AAC.45.2.454-459.2001. View

18.

Cui L, Iwamoto A, Lian J, Neoh H, Maruyama T, Horikawa Y . Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(2):428-38. PMC: 1366884. DOI: 10.1128/AAC.50.2.428-438.2006. View

19.

Akins R, Rybak M . In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother. 2000; 44(7):1925-9. PMC: 89987. DOI: 10.1128/AAC.44.7.1925-1929.2000. View